La cadena de opciones muestra datos clave de las opciones de acciones de RAPT Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para RAPT Therapeutics..

RAPT Therapeutics (NASDAQ:RAPT) Bolsa, Cadena de Opciones

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Inc

RAPT rockets 180% on licensing deal, $150M private placement (update)

Leerink Partners analyst Thomas Smith has maintained their neutral stance on RAPT stock, giving a Hold rating on December 12. Thomas Smith's rating...

Cautious Hold Recommendation for RAPT Therapeutics Amid Strategic Acquisition and Market Uncertainties

H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Grou...

Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju upgraded RAPT Therapeutics (RAPT – Research Report) to a Buy on December 24 and set a price target of $10.00....

Positive Report for RAPT Therapeutics (RAPT) from H.C. Wainwright

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Rapt Therapeutics (RAPT) up 5% after H.C. Wainwright upg...

Morning Movers: Rapt Therapeutics rises after upgrade

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Progressive, EverQuote upgraded: Wall Street's top analyst calls

RAPT upgraded at H.C. Wainwright on China licensing deal

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Nippon Steel (NPSCY) pushes out expect...

Wedbush hikes Apple target to high on Street: Morning Buzz

US stock futures and Treasuries dropped as muted trading resumed after the Christmas holiday, with investors looking to initial jobless claims data and a government bond auction later on Thursday.

Futures Slide As Bond Yields Jump To 6 Month High

AAPL

ACRS

AEHR

APOG

AVXL

BABA

CALM

COST

DLVHF

EVER

FGEN

GOOG

GOOGL

HGTY

KULR

LAES

MSFT

MSTR

NFLX

NISTF

NNDM

NPSCY

ONCY

PBYI

PHIO

PVLA

RAPT

RHHBF

RHHBY

RIOT

SBUX

SLGL

SSNLF

SVNDF

SVNDY

UBER

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

News

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

RAPT Therapeutics Announces $150 Million Private Placement

Agenus

AlloVir

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Citius Oncology

Cue Biopharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immix Biopharma

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Invivyd

Kronos Bio

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Mural Oncology

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Repare Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Shattuck Labs

Vigil Neuroscience

Vor Biopharma

Exicure

Xilio Therapeutics

HC Wainwright & Co.

Wells Fargo

Barclays

Leerink Partners

Comments

RAPT Therapeutics

RAPT Therapeutics (RAPT) Opciones

RAPT Therapeutics (NASDAQ:RAPT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL